<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03927911</url>
  </required_header>
  <id_info>
    <org_study_id>402-C-413</org_study_id>
    <nct_id>NCT03927911</nct_id>
  </id_info>
  <brief_title>Phase 4 Study in Adult Subjects Undergoing Posterior Lumbar Spine Surgeries</brief_title>
  <acronym>FUSION</acronym>
  <official_title>A Multicenter, Prospective, Active Controlled, Real World, Phase 4 Study of EXPAREL in Multimodal Regimens Compared With Standard of Care for Postsurgical Pain Management in Subjects Undergoing Lumbar Posterior Spine Surgeries (FUSION)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pacira Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pacira Pharmaceuticals, Inc</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective: The primary objective of this study is to compare postsurgical opioid&#xD;
      consumption through 72 hours postsurgery in patients receiving local infiltration analgesia&#xD;
      (LIA) with EXPAREL and bupivacaine HCl (EXPAREL group) with that of patients receiving&#xD;
      standard of care (SOC) (control group) in adult subjects undergoing posterior lumbar spine&#xD;
      surgeries where both groups are receiving a multimodal pain regimen.&#xD;
&#xD;
      Secondary Objectives: The secondary objectives of this study are to:&#xD;
&#xD;
        1. Compare safety and effectiveness outcomes following LIA with EXPAREL and bupivacaine&#xD;
           hydrochloride (HCl) versus SOC in adult subjects undergoing posterior lumbar spine&#xD;
           surgeries through 72 hours, including time to first opioid and opioid-related adverse&#xD;
           events (ORAEs).&#xD;
&#xD;
        2. Compare health outcomes following LIA with EXPAREL and bupivacaine hydrochloride (HCl)&#xD;
           versus SOC in adult subjects undergoing posterior lumbar spine surgeries, including&#xD;
           discharge readiness, hospital (or other facility) length of stay (LOS), discharge&#xD;
           disposition, hospital readmissions, and health service utilization.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 4, multicenter, prospective, active-controlled, real world, study in&#xD;
      approximately 225 adult subjects undergoing posterior lumbar spine surgery under general&#xD;
      anesthesia.&#xD;
&#xD;
      Subjects will be screened within 30 days prior to surgery; screening on the day of surgery&#xD;
      will be allowed but is discouraged. If a subject can only be screened on the day of surgery,&#xD;
      the informed consent process must still be started at least 24 hours prior to the conduct of&#xD;
      any screening procedures that are not considered SOC at the institution and such procedures&#xD;
      may not be performed until written informed consent is provided. All screening procedures&#xD;
      that are not SOC must be performed and documented within the 30-day time window (inclusive of&#xD;
      the day of surgery for those subjects who can only be screened on the day of surgery) as&#xD;
      described here.&#xD;
&#xD;
      During the screening visit, subjects will be assessed for any past or present medical&#xD;
      conditions that in the opinion of the investigator would preclude them from study&#xD;
      participation. After the ICF is signed, the following information will be recorded and&#xD;
      procedures done: medical history, surgical history, medication history, the subject's opioid&#xD;
      use history will be recorded to calculate mean daily mg oral morphine equivalent dosing (MED&#xD;
      PO) in the last 30 days, demographic and background information, height, weight and body mass&#xD;
      index (BMI), a urine pregnancy test for women of childbearing potential, and the subject's&#xD;
      current adverse experiences (AEs), if any.&#xD;
&#xD;
      Subjects will be asked questions and/or be asked to fill forms as part of the following&#xD;
      assessments: Brief Pain Inventory - short form (BPI-sf), 5-item Opioid Compliance Checklist&#xD;
      (OCC), Hospital Anxiety and Depression Scale (HADS), Survey of Pain Attitudes (SOPA), Numeric&#xD;
      Rating Scale (NRS) ti assess pain and Opioid Related Symptom Distress Scale (ORSDS).&#xD;
&#xD;
      Based on the planned surgical procedure, subjects will be placed in one of three cohorts:&#xD;
&#xD;
        -  Cohort 1 - Open lumbar spinal fusion technique; (&quot;open&quot; cohort)&#xD;
&#xD;
        -  Cohort 2 - Minimally invasive tubular and/or percutaneous pedicle screw insertion for&#xD;
           lumbar decompression with or without fusion;(&quot;tubular/percutaneous without midline&#xD;
           incision&quot; cohort)&#xD;
&#xD;
        -  Cohort 3 - Lumbar decompression surgery (LDS) without fusion (discectomy or laminectomy&#xD;
           outpatient cohort)&#xD;
&#xD;
      The initial sample size in each study cohort (i.e., cohort 1, cohort 2 and cohort 3) is&#xD;
      estimated at 75 subjects (50 subjects with EXPAREL and 25 subjects with Control group), for a&#xD;
      total of 225 subjects in all three cohorts. Within each assigned cohort, subjects will be&#xD;
      allocated in a 2:1 ratio to the EXPAREL (50 subjects) and Control group (25 subjects).&#xD;
&#xD;
      The following sequence will be followed for all cohorts: First, the subjects who meet&#xD;
      eligibility criteria will be treated according to the institution's SOC. Their data will be&#xD;
      collected prospectively. Next, at each investigational site, the administration of EXPAREL&#xD;
      and bupivacaine HCl to the first 1 to 3 subjects in each cohort will be observed to ensure&#xD;
      that the correct procedure for infiltration as described in the infiltration guide is being&#xD;
      followed. If the infiltration was performed correctly, the subject will be included in the&#xD;
      study. If the infiltration was performed incorrectly, the subject will continue in the study&#xD;
      but will be removed from statistical analysis and will be replaced to ensure at least 50&#xD;
      evaluable EXPAREL patients are enrolled per cohort. If subjects are discontinued for other&#xD;
      reasons, they will be replaced such that a total sample size of 75 fully evaluable subjects&#xD;
      is obtained in each study cohort, with 50 in the EXPAREL group and 25 in the Control group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to protocol feasibility given the rapid evolution of medical practice for spinal procedure.&#xD;
    Data from approximately 65 FUSION study subjects will be analyzed with the intent to create&#xD;
    either a future study or registry for this patient population.&#xD;
  </why_stopped>
  <start_date type="Actual">July 31, 2019</start_date>
  <completion_date type="Actual">August 4, 2020</completion_date>
  <primary_completion_date type="Actual">August 4, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-surgical Opioid Consumption in mg MED PO (0-72 Hours)</measure>
    <time_frame>0-72 hours</time_frame>
    <description>Post-surgical opioid consumption in mg MED PO from 0 hours (end of surgery) to 72 hours postsurgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-surgical Opioid Consumption in mg MED PO at 14 Days After Surgery</measure>
    <time_frame>0-14 days after surgery</time_frame>
    <description>Post-surgical opioid consumption in mg MED PO at 14 days after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Opioid Rescue Through 72 Hours or Discharge.</measure>
    <time_frame>0-72 hours</time_frame>
    <description>Time to first opioid rescue through 72 hours or discharge.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Postoperative Pain Management</condition>
  <arm_group>
    <arm_group_label>Open or mini-open surgical technique cohort</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Local infiltration Analgesia administered (with EXPAREL and bupivacaine HCl) in EXPAREL arm within cohort. EXPAREL arm to be compared to SOC arm within cohort</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tubular or Percutaneous cohort (Minimally Invasive Cohort)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Local infiltration Analgesia administered (with EXPAREL and bupivacaine HCl) in EXPAREL arm within cohort. EXPAREL arm to be compared to SOC arm within cohort</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lumbar decompression without fusion (Outpatient Cohort)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Local infiltration Analgesia administered (with EXPAREL and bupivacaine HCl) in EXPAREL arm within cohort. EXPAREL arm to be compared to SOC arm within cohort</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EXPAREL and Bupivacaine</intervention_name>
    <description>Drug: EXPAREL and Bupivacaine HCl 0.5%</description>
    <arm_group_label>Lumbar decompression without fusion (Outpatient Cohort)</arm_group_label>
    <arm_group_label>Open or mini-open surgical technique cohort</arm_group_label>
    <arm_group_label>Tubular or Percutaneous cohort (Minimally Invasive Cohort)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Standard of Care</description>
    <arm_group_label>Lumbar decompression without fusion (Outpatient Cohort)</arm_group_label>
    <arm_group_label>Open or mini-open surgical technique cohort</arm_group_label>
    <arm_group_label>Tubular or Percutaneous cohort (Minimally Invasive Cohort)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18-75 years old at the time of screening.&#xD;
&#xD;
          2. Primary surgical indication is related to spinal degenerative disease, including any&#xD;
             of the following:&#xD;
&#xD;
               1. Spinal stenosis&#xD;
&#xD;
               2. Spondylolisthesis&#xD;
&#xD;
               3. Radiculopathy/instability disc disorders&#xD;
&#xD;
               4. Degenerative disc disease&#xD;
&#xD;
          3. Medically cleared for elective spine surgery.&#xD;
&#xD;
          4. Scheduled to undergo:&#xD;
&#xD;
               1. Elective (i.e., not emergency)&#xD;
&#xD;
               2. Lumbosacral (i.e., L1-S1)&#xD;
&#xD;
               3. Posterior approach with posterior instrumentation&#xD;
&#xD;
          5. Cohort 1 - Open only:&#xD;
&#xD;
             Open or mini-open surgical technique with:&#xD;
&#xD;
               1. 1-level (i.e., spanning 2 vertebrae) or 2-level (i.e., spanning 3 contiguous&#xD;
                  vertebrae)&#xD;
&#xD;
               2. Primary fusion or revision fusion&#xD;
&#xD;
               3. Open or mini-open surgical technique&#xD;
&#xD;
          6. Cohort 2 - Tubular or percutaneous cohort only:&#xD;
&#xD;
               1. 1-level (i.e., spanning 2 vertebrae) or 2-level (i.e., spanning 3 contiguous&#xD;
                  vertebrae)&#xD;
&#xD;
               2. Primary fusion or revision fusion&#xD;
&#xD;
               3. Tubular or percutaneous surgical technique&#xD;
&#xD;
          7. Cohort 3 - Lumbar decompression without fusion outpatient cohort only:&#xD;
&#xD;
               1. Radiculopathy&#xD;
&#xD;
               2. Spinal stenosis&#xD;
&#xD;
          8. Able to provide informed consent and adhere to all study assessments and visit&#xD;
             schedule&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Serious spinal pathology determined by Investigator that might meaningfully affect&#xD;
             postsurgical outcomes, including any of the following:&#xD;
&#xD;
               1. Suspected cauda equina syndrome (e.g., bowel/bladder involvement)&#xD;
&#xD;
               2. Infection&#xD;
&#xD;
               3. Tumor&#xD;
&#xD;
               4. Fracture&#xD;
&#xD;
               5. Systemic inflammatory spondyloarthropathy&#xD;
&#xD;
          2. Contraindication to local anesthesia according to the clinical judgment of the&#xD;
             Investigator and based on the EXPAREL label.&#xD;
&#xD;
          3. Patients who most likely will require patient-controlled analgesia (PCA) pumps in&#xD;
             EXPAREL group.&#xD;
&#xD;
          4. Anterior surgical approaches, including any of the following:&#xD;
&#xD;
               1. Anterior lumbar interbody fusion (ALIF)&#xD;
&#xD;
               2. Oblique lumbar interbody fusion (OLIF)&#xD;
&#xD;
               3. Anterior-posterior or 360ยบ fusion&#xD;
&#xD;
          5. Lateral surgical approaches, including any of the following:&#xD;
&#xD;
               1. Extreme lateral interbody fusion (XLIF)&#xD;
&#xD;
               2. Direct lateral interbody fusion (DLIF)&#xD;
&#xD;
          6. High-dose presurgical opioid use:&#xD;
&#xD;
             a) Mean daily intake greater than 100 mg mEq PO in the past 30 days&#xD;
&#xD;
          7. Known allergy, hypersensitivity, or contraindication to any of the following study&#xD;
             medications:&#xD;
&#xD;
               1. Bupivacaine&#xD;
&#xD;
               2. EXPAREL&#xD;
&#xD;
               3. Tylenol (acetaminophen)&#xD;
&#xD;
               4. Robaxin&#xD;
&#xD;
               5. 2 or more NSAIDs&#xD;
&#xD;
               6. 2 or more gabapentinoids&#xD;
&#xD;
               7. 2 or more rescue opioids (e.g., oxycodone, morphine, hydromorphone)&#xD;
&#xD;
               8. 2 or more medications for postoperative nausea, vomiting, or pruritus (e.g.,&#xD;
                  dexamethasone, ondansetron)&#xD;
&#xD;
          8. History of severely impaired renal or hepatic function.&#xD;
&#xD;
          9. Severe chronic pain that requires analgesic treatment, and in the opinion of the&#xD;
             principal Investigator, is likely to meaningfully affect postsurgical outcomes.&#xD;
&#xD;
         10. Subjects that have implanted spinal cord stimulator or intrathecal drug pump.&#xD;
&#xD;
         11. Any neurologic or psychiatric disorder that might impact postsurgical pain or&#xD;
             interfere with study assessments per Investigator discretion.&#xD;
&#xD;
         12. Malignancy in the last 2 years.&#xD;
&#xD;
         13. History of misuse, abuse, or dependence on opioid analgesics, other prescription&#xD;
             drugs, illicit drugs, or alcohol as defined in DSM-5 (Diagnostic and Statistical&#xD;
             Manual of Mental Disorders, Fifth Edition). Dependence or chronic opioid use will be&#xD;
             defined as use of more than 30 morphine equivalents per day during the prior 90 days.&#xD;
&#xD;
         14. Currently pregnant, nursing, or planning to become pregnant during the study or within&#xD;
             1 month after study drug administration.&#xD;
&#xD;
         15. Body Mass Index &lt; 17 kg/m2 or &gt;44 kg/m2 at screening&#xD;
&#xD;
         16. Subjects receiving Worker's Compensation for disability or who are involved in other&#xD;
             litigation related to the spine.&#xD;
&#xD;
         17. Planned concurrent surgical procedure.&#xD;
&#xD;
         18. Previous participation in an EXPAREL study.&#xD;
&#xD;
         19. Administration of any investigational drug within 30 days or 5 elimination half-lives&#xD;
             of such investigational drug, whichever is longer, prior to study drug administration,&#xD;
             or planned administration of another investigational product or procedure during the&#xD;
             subject's participation in this study.&#xD;
&#xD;
        In addition, the subject might be excluded from the study prior to study drug infiltration&#xD;
        if one of the following criteria during the surgical procedure is met:&#xD;
&#xD;
          1. Unable to place planned surgical instrumentation&#xD;
&#xD;
          2. Poor fixation at the time of surgical instrumentation&#xD;
&#xD;
        In addition, the subject must be considered an early termination if one of the following&#xD;
        criteria after the surgical procedure is met:&#xD;
&#xD;
          1. An incision size &gt;20 cm&#xD;
&#xD;
          2. Autograft taken from a harvest site other than surgical site (i.e., iliac crest&#xD;
             autograft)&#xD;
&#xD;
          3. Intraoperative complications likely to meaningfully affect postsurgical outcomes,&#xD;
             including any of the following:&#xD;
&#xD;
               1. Clinically significant and prolonged (i.e., &gt;24 hours) neurologic deficit (e.g.,&#xD;
                  foot drop)&#xD;
&#xD;
               2. Dural tear or suspected dural tear requiring bed rest (exception: subject will be&#xD;
                  allowed if the dural tear is fixed as per SOC of the institution during surgery)&#xD;
&#xD;
               3. Extensive bleeding (i.e., &gt;1,000 mL blood loss)&#xD;
&#xD;
               4. Symptomatic epidural hematoma&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary Nevins, DC</last_name>
    <role>Study Director</role>
    <affiliation>Pacira Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marcus Neuroscience Institute</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NorthShore University HealthSystem</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Orthopaedic Institute of Western Kentucky</name>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <zip>42003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bronson Methodist Hospital</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina NeuroSurgery &amp; Spine Associates, P.A.</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M3-Emerging Medical Research, LLC</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summit Spine Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Surgical Hospital</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 19, 2019</study_first_submitted>
  <study_first_submitted_qc>April 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2019</study_first_posted>
  <results_first_submitted>August 30, 2021</results_first_submitted>
  <results_first_submitted_qc>October 12, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">November 9, 2021</results_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 25, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/11/NCT03927911/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 19, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/11/NCT03927911/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Subject might be excluded from the study prior to study drug infiltration if one of the following criteria during the surgical procedure is met:&#xD;
Unable to place planned surgical instrumentation&#xD;
Poor fixation at the time of surgical instrumentation</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1:Open or Mini-open Surgical Technique</title>
          <description>Local infiltration Analgesia administered (with EXPAREL and bupivacaine HCl) in EXPAREL arm within cohort. EXPAREL arm to be compared to SOC arm within cohort&#xD;
EXPAREL and Bupivacaine: Drug: EXPAREL and Bupivacaine HCl 0.5%&#xD;
Standard of Care: Standard of Care</description>
        </group>
        <group group_id="P2">
          <title>Cohort 1 Control Group</title>
          <description>Standard of Care</description>
        </group>
        <group group_id="P3">
          <title>Cohort 2: Tubular or Percutaneous (Minimally Invasive Cohort)</title>
          <description>Local infiltration Analgesia administered (with EXPAREL and bupivacaine HCl) in EXPAREL arm within cohort. EXPAREL arm to be compared to SOC arm within cohort&#xD;
EXPAREL and Bupivacaine: Drug: EXPAREL and Bupivacaine HCl 0.5%&#xD;
Standard of Care: Standard of Care</description>
        </group>
        <group group_id="P4">
          <title>Cohort 2 Control Group</title>
          <description>Standard of Care</description>
        </group>
        <group group_id="P5">
          <title>Cohort 3: Lumbar Decompression Without Fusion (Outpatient Cohort)</title>
          <description>Local infiltration Analgesia administered (with EXPAREL and bupivacaine HCl) in EXPAREL arm within cohort. EXPAREL arm to be compared to SOC arm within cohort&#xD;
EXPAREL and Bupivacaine: Drug: EXPAREL and Bupivacaine HCl 0.5%&#xD;
Standard of Care: Standard of Care</description>
        </group>
        <group group_id="P6">
          <title>Cohort 3 Control Group</title>
          <description>Standard of Care</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="13"/>
                <participants group_id="P6" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="13"/>
                <participants group_id="P6" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>problems with eDiary</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>not treated -study terminated by sponsor</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Surgery cancelled</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Trial was terminated, not all arms had participants enrolled.</population>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1:Open or Mini-open Surgical Technique</title>
          <description>Local infiltration Analgesia administered (with EXPAREL and bupivacaine HCl) in EXPAREL arm within cohort. EXPAREL arm to be compared to SOC arm within cohort&#xD;
EXPAREL and Bupivacaine: Drug: EXPAREL and Bupivacaine HCl 0.5%&#xD;
Standard of Care: Standard of Care</description>
        </group>
        <group group_id="B2">
          <title>Cohort 1 Control Group</title>
          <description>Standard of Care</description>
        </group>
        <group group_id="B3">
          <title>Cohort 2: Tubular or Percutaneous (Minimally Invasive Cohort)</title>
          <description>Local infiltration Analgesia administered (with EXPAREL and bupivacaine HCl) in EXPAREL arm within cohort. EXPAREL arm to be compared to SOC arm within cohort&#xD;
EXPAREL and Bupivacaine: Drug: EXPAREL and Bupivacaine HCl 0.5%&#xD;
Standard of Care: Standard of Care</description>
        </group>
        <group group_id="B4">
          <title>Cohort 2 Control Group</title>
          <description>Standard of Care</description>
        </group>
        <group group_id="B5">
          <title>Cohort 3: Lumbar Decompression Without Fusion (Outpatient Cohort)</title>
          <description>Local infiltration Analgesia administered (with EXPAREL and bupivacaine HCl) in EXPAREL arm within cohort. EXPAREL arm to be compared to SOC arm within cohort&#xD;
EXPAREL and Bupivacaine: Drug: EXPAREL and Bupivacaine HCl 0.5%&#xD;
Standard of Care: Standard of Care</description>
        </group>
        <group group_id="B6">
          <title>Cohort 3 Control Group</title>
          <description>Standard of Care</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="0"/>
            <count group_id="B4" value="3"/>
            <count group_id="B5" value="13"/>
            <count group_id="B6" value="32"/>
            <count group_id="B7" value="65"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="60.94" lower_limit="47" upper_limit="75"/>
                    <measurement group_id="B4" value="56" lower_limit="53" upper_limit="60"/>
                    <measurement group_id="B5" value="52.38" lower_limit="22" upper_limit="74"/>
                    <measurement group_id="B6" value="52.66" lower_limit="21" upper_limit="72"/>
                    <measurement group_id="B7" value="55.495" lower_limit="21" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="11"/>
                    <measurement group_id="B7" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="21"/>
                    <measurement group_id="B7" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="27"/>
                    <measurement group_id="B7" value="58"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="29"/>
                    <measurement group_id="B7" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="32"/>
                    <measurement group_id="B7" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Post-surgical Opioid Consumption in mg MED PO (0-72 Hours)</title>
        <description>Post-surgical opioid consumption in mg MED PO from 0 hours (end of surgery) to 72 hours postsurgery</description>
        <time_frame>0-72 hours</time_frame>
        <population>Trial was terminated, not all arms had participants enrolled.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1:Open or Mini-open Surgical Technique</title>
            <description>Local infiltration Analgesia administered (with EXPAREL and bupivacaine HCl) in EXPAREL arm within cohort. EXPAREL arm to be compared to SOC arm within cohort&#xD;
EXPAREL and Bupivacaine: Drug: EXPAREL and Bupivacaine HCl 0.5%&#xD;
Standard of Care: Standard of Care</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 Control Group</title>
            <description>Standard of Care</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2: Tubular or Percutaneous (Minimally Invasive Cohort)</title>
            <description>Local infiltration Analgesia administered (with EXPAREL and bupivacaine HCl) in EXPAREL arm within cohort. EXPAREL arm to be compared to SOC arm within cohort&#xD;
EXPAREL and Bupivacaine: Drug: EXPAREL and Bupivacaine HCl 0.5%&#xD;
Standard of Care: Standard of Care</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2 Control Group</title>
            <description>Standard of Care</description>
          </group>
          <group group_id="O5">
            <title>Cohort 3: Lumbar Decompression Without Fusion (Outpatient Cohort)</title>
            <description>Local infiltration Analgesia administered (with EXPAREL and bupivacaine HCl) in EXPAREL arm within cohort. EXPAREL arm to be compared to SOC arm within cohort&#xD;
EXPAREL and Bupivacaine: Drug: EXPAREL and Bupivacaine HCl 0.5%&#xD;
Standard of Care: Standard of Care</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3 Control Group</title>
            <description>Standard of Care</description>
          </group>
        </group_list>
        <measure>
          <title>Post-surgical Opioid Consumption in mg MED PO (0-72 Hours)</title>
          <description>Post-surgical opioid consumption in mg MED PO from 0 hours (end of surgery) to 72 hours postsurgery</description>
          <population>Trial was terminated, not all arms had participants enrolled.</population>
          <units>MED, mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="90.7" spread="96.91"/>
                    <measurement group_id="O4" value="56.8" spread="5.30"/>
                    <measurement group_id="O5" value="51.6" spread="60.98"/>
                    <measurement group_id="O6" value="83.6" spread="109.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-surgical Opioid Consumption in mg MED PO at 14 Days After Surgery</title>
        <description>Post-surgical opioid consumption in mg MED PO at 14 days after surgery</description>
        <time_frame>0-14 days after surgery</time_frame>
        <population>Trial was terminated, not all arms had participants enrolled.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1:Open or Mini-open Surgical Technique</title>
            <description>Local infiltration Analgesia administered (with EXPAREL and bupivacaine HCl) in EXPAREL arm within cohort. EXPAREL arm to be compared to SOC arm within cohort&#xD;
EXPAREL and Bupivacaine: Drug: EXPAREL and Bupivacaine HCl 0.5%&#xD;
Standard of Care: Standard of Care</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 Control Group</title>
            <description>Standard of Care</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2: Tubular or Percutaneous (Minimally Invasive Cohort)</title>
            <description>Local infiltration Analgesia administered (with EXPAREL and bupivacaine HCl) in EXPAREL arm within cohort. EXPAREL arm to be compared to SOC arm within cohort&#xD;
EXPAREL and Bupivacaine: Drug: EXPAREL and Bupivacaine HCl 0.5%&#xD;
Standard of Care: Standard of Care</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2 Control Group</title>
            <description>Standard of Care</description>
          </group>
          <group group_id="O5">
            <title>Cohort 3: Lumbar Decompression Without Fusion (Outpatient Cohort)</title>
            <description>Local infiltration Analgesia administered (with EXPAREL and bupivacaine HCl) in EXPAREL arm within cohort. EXPAREL arm to be compared to SOC arm within cohort&#xD;
EXPAREL and Bupivacaine: Drug: EXPAREL and Bupivacaine HCl 0.5%&#xD;
Standard of Care: Standard of Care</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3 Control Group</title>
            <description>Standard of Care</description>
          </group>
        </group_list>
        <measure>
          <title>Post-surgical Opioid Consumption in mg MED PO at 14 Days After Surgery</title>
          <description>Post-surgical opioid consumption in mg MED PO at 14 days after surgery</description>
          <population>Trial was terminated, not all arms had participants enrolled.</population>
          <units>MED, mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="279" spread="330.66"/>
                    <measurement group_id="O4" value="330.8" spread="42.78"/>
                    <measurement group_id="O5" value="158.4" spread="242.71"/>
                    <measurement group_id="O6" value="187.7" spread="252.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Opioid Rescue Through 72 Hours or Discharge.</title>
        <description>Time to first opioid rescue through 72 hours or discharge.</description>
        <time_frame>0-72 hours</time_frame>
        <population>Trial was terminated, not all arms had participants enrolled.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1:Open or Mini-open Surgical Technique</title>
            <description>Local infiltration Analgesia administered (with EXPAREL and bupivacaine HCl) in EXPAREL arm within cohort. EXPAREL arm to be compared to SOC arm within cohort&#xD;
EXPAREL and Bupivacaine: Drug: EXPAREL and Bupivacaine HCl 0.5%&#xD;
Standard of Care: Standard of Care</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 Control Group</title>
            <description>Standard of Care</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2: Tubular or Percutaneous (Minimally Invasive Cohort)</title>
            <description>Local infiltration Analgesia administered (with EXPAREL and bupivacaine HCl) in EXPAREL arm within cohort. EXPAREL arm to be compared to SOC arm within cohort&#xD;
EXPAREL and Bupivacaine: Drug: EXPAREL and Bupivacaine HCl 0.5%&#xD;
Standard of Care: Standard of Care</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2 Control Group</title>
            <description>Standard of Care</description>
          </group>
          <group group_id="O5">
            <title>Cohort 3: Lumbar Decompression Without Fusion (Outpatient Cohort)</title>
            <description>Local infiltration Analgesia administered (with EXPAREL and bupivacaine HCl) in EXPAREL arm within cohort. EXPAREL arm to be compared to SOC arm within cohort&#xD;
EXPAREL and Bupivacaine: Drug: EXPAREL and Bupivacaine HCl 0.5%&#xD;
Standard of Care: Standard of Care</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3 Control Group</title>
            <description>Standard of Care</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Opioid Rescue Through 72 Hours or Discharge.</title>
          <description>Time to first opioid rescue through 72 hours or discharge.</description>
          <population>Trial was terminated, not all arms had participants enrolled.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.82" lower_limit="0.58" upper_limit="8.02"/>
                    <measurement group_id="O4" value="0.36" lower_limit="0.03" upper_limit="0.68"/>
                    <measurement group_id="O5" value="3.07" lower_limit="0.60" upper_limit="25.10"/>
                    <measurement group_id="O6" value="0.95" lower_limit="0.83" upper_limit="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs were collected from time of signing informed consent to Day 30 phone call.</time_frame>
      <desc>Any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1:Open or Mini-open Surgical Technique</title>
          <description>Local infiltration Analgesia administered (with EXPAREL and bupivacaine HCl) in EXPAREL arm within cohort. EXPAREL arm to be compared to SOC arm within cohort&#xD;
EXPAREL and Bupivacaine: Drug: EXPAREL and Bupivacaine HCl 0.5%&#xD;
Standard of Care: Standard of Care</description>
        </group>
        <group group_id="E2">
          <title>Cohort 1 Control Group</title>
          <description>Standard of Care for open or mini-open surgical technique cohort</description>
        </group>
        <group group_id="E3">
          <title>Cohort 2: Tubular or Percutaneous (Minimally Invasive Cohort)</title>
          <description>Local infiltration Analgesia administered (with EXPAREL and bupivacaine HCl) in EXPAREL arm within cohort. EXPAREL arm to be compared to SOC arm within cohort&#xD;
EXPAREL and Bupivacaine: Drug: EXPAREL and Bupivacaine HCl 0.5%&#xD;
Standard of Care: Standard of Care</description>
        </group>
        <group group_id="E4">
          <title>Cohort 2 Control Group</title>
          <description>Standard of Care for Tubular or Percutaneous Cohort (Minimally Invasive Cohort)</description>
        </group>
        <group group_id="E5">
          <title>Cohort 3: Lumbar Decompression Without Fusion (Outpatient Cohort)</title>
          <description>Local infiltration Analgesia administered (with EXPAREL and bupivacaine HCl) in EXPAREL arm within cohort. EXPAREL arm to be compared to SOC arm within cohort&#xD;
EXPAREL and Bupivacaine: Drug: EXPAREL and Bupivacaine HCl 0.5%&#xD;
Standard of Care: Standard of Care</description>
        </group>
        <group group_id="E6">
          <title>Cohort 3 Control Group</title>
          <description>Standard of Care for Limbar decompression without fusion (Outpatient Cohort)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Lumbar Spinal Stenosis</sub_title>
                <counts group_id="E1" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cauda equina syndrome</sub_title>
                <counts group_id="E1" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="2"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Spinal epidural haematoma</sub_title>
                <counts group_id="E1" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E6" events="7" subjects_affected="7" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Purulent discharge</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Stitch abcess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Extradural Hematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Postoperative wound complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" events="9" subjects_affected="9" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Results conducted at Site shall not be published before 1st multicenter publication by Sponsor but can proceed if there is no such publication โค18 months after study completion/termination at all sites and all data have been received. Before submitting manuscript/materials to an outside person/entity, site shall give Sponsor 60 days to review and comment. Site shall, upon request, further delay publication/presentation for โค120 days to allow Sponsor to protect its interests in Inventions.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pacira Medical Information</name_or_title>
      <organization>Pacira Pharmaceuticals</organization>
      <phone>1-855-793-9727</phone>
      <email>MedInfo@pacira.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

